Shandong Xinhua Pharmaceutical Co (HKSE:00719) 3-Year Book Growth Rate : 9.20% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co 3-Year Book Growth Rate?

Shandong Xinhua Pharmaceutical Co's Book Value per Share for the quarter that ended in Mar. 2024 was HK$7.59.

During the past 12 months, Shandong Xinhua Pharmaceutical Co's average Book Value per Share Growth Rate was 8.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was 9.20% per year. During the past 5 years, the average Book Value per Share Growth Rate was 9.10% per year. During the past 10 years, the average Book Value per Share Growth Rate was 9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Shandong Xinhua Pharmaceutical Co was 13.80% per year. The lowest was -1.50% per year. And the median was 6.75% per year.

Competitive Comparison of Shandong Xinhua Pharmaceutical Co's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Xinhua Pharmaceutical Co's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's 3-Year Book Growth Rate falls into.

Shandong Xinhua Pharmaceutical Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Shandong Xinhua Pharmaceutical Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

XIN:Germany 000756:China

Address

No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086

Website

http://www.xhzy.com

Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Headlines

No Headlines